International Journal of Cancer · 2010 · 54 citations · 26 references
MedicineImmunologyOncologyCancer ImmunologyMetastasisTumor ImmunologyColorectal CancerImmune Cell InfiltrationT Cell Responses To TumorsTumor AntigensTumor Immune MicroenvironmentTumor-infiltrating LymphocytesCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesCd8 Positive T CellsCd8+ Tumor-infiltrating LymphocytesReactive LymphocytesT-cell Responses To Tumor AntigensTumor Immune Cell InfiltrationTumor Reactivity
High level of T-cell infiltration in colorectal carcinomas (CRCs) is a good prognostic indicator, but the tumor reactivity of this infiltrate (tumor infiltrating lymphocytes [TIL]) is poorly documented. This study examined the presence, phenotype and functional features of tumor-reactive lymphocytes in human CRC. Freshly dissociated TIL and T cell lines were isolated from CRC samples and from some paired normal colonic mucosa. Four tumor cell lines were obtained. Autologous tumor reactivity of CRC TIL and tumor-reactive cell features were analyzed. We demonstrate the presence among CRC TIL of variable fractions (up to 18%) of double positive CD4(+) CD8αβ(+) (DP) αβ T cells. Interestingly, a high proportion (16-20%) of this TIL subset displayed tumor reactivity, whilst this was the case for no or few single positive TIL. Low levels of DP TIL were found in most CRC samples and in normal colonic mucosa, but these cells were higher in metastatic CRC. Furthermore, we showed that DP TIL were polyclonal, restricted by HLA class-I, proliferated poorly and secreted higher amounts of IL-4 and IL-13 than single positive T cells, on cognate or CD3 stimulation. DP CRC TIL also expressed CD103, confirming their mucosal origin. Increased frequencies of tumor-reactive DP TIL in metastatic CRC suggest that these cells play a role in the metastatic process of this cancer. Based on their high secretion of IL-4 and IL-13 and on previously described roles of these cytokines in cancers, we postulate that DP TIL could favor CRC growth or metastasis and/or downmodulate immune responses to these tumors.
26
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Paul T. Golumbek, Audrey J. Lazenby, Hyam I. Levitsky et al. · Science · 1991 · 731 citations
Medicine, Immunology, Oncology +17
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells
Joërg Mattes, Mark D. Hulett, Wei Xie et al. · The Journal of Experimental Medicine · 2003 · 247 citations · Full text
Life Sciences, Immunology, Oncology +17